Quest Diagnostics Lifts Full-Year 2026 Revenue and EPS Outlook
DGX sits 38% above its 52-week low of $171.175.
Summary
Quest raised its full-year 2026 revenue and EPS guidance after posting Q3 revenue of $3.10 billion, up 10.0%, and adjusted EPS of $3.00, up 15.4%. That follows Q2 revenue of $3.04 billion (+10.2%) and a prior hike to full-year adjusted EPS of $11.05–$11.25, so this is the second upward revision in two quarters. The stock is trading near its 52-week high, so the bar was already elevated. Same-day 8-K also disclosed unauthorized access to the Quanum LSM ordering and results system on October 21, 2026 — an operational risk sitting alongside the beat.
At the time of this announcement, DGX was trading at $236.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.1B. The 52-week trading range was $171.18 to $248.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.